Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism

  • Authors:
    • Qiong‑Fang Yang
    • Ting‑Ting Lu
    • Cai‑Min Shu
    • Lan‑Fang Feng
    • Hao‑Teng Chang
    • Qiao‑Ying Ji
  • View Affiliations

  • Published online on: August 2, 2017     https://doi.org/10.3892/etm.2017.4876
  • Pages: 3198-3206
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Eosinophilia has been implicated in the pathophysiology of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the role of eosinophil activation in the development of AECOPD remains unclear. In the present study, the reliability of plasma levels of eosinophil activation markers, including eosinophil cationic protein (ECP), major basic protein (MBP), eosinophil‑derived neurotoxin (EDN) and eosinophil peroxidase (EPX), were measured and used as diagnostic biomarkers of AECOPD with or without pulmonary embolism (PE). A total of 47 patients with AECOPD, 30 patients with AECOPD/PE and 35 healthy adults were enrolled in the present study. Plasma levels of ECP, EDN, EPX and MBP were measured using commercial ELISA kits. The mean concentrations of plasma ECP, EDN, EPX and MBP in the patients with AECOPD was significantly 2.87‑, 3.06‑, 1.60‑ and 1.92‑fold higher, respectively, compared with the control group (P<0.05). Similar results were obtained in patients with AECOPD/PE, for whom plasma levels of ECP, EDN, EPX and MBP were significantly 2.06‑, 2.21‑, 1.42‑ and 2.42‑fold higher, respectively, compared with the controls (P<0.05). No significant differences were observed in the levels of these proteins between patients with AECOPD or AECOPD/PE. Among the four potential markers, ECP was determined to be the optimal marker for distinguishing patients with AECOPD or AECOPD/PE from the controls. No significant correlation was observed between marker concentrations and gender, age or disease severity. The results of the present study may have clinical applications in the diagnosis of AECOPD using these novel biomarkers.

Related Articles

Journal Cover

October-2017
Volume 14 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang QF, Lu TT, Shu CM, Feng LF, Chang HT and Ji QY: Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism. Exp Ther Med 14: 3198-3206, 2017
APA
Yang, Q., Lu, T., Shu, C., Feng, L., Chang, H., & Ji, Q. (2017). Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism. Experimental and Therapeutic Medicine, 14, 3198-3206. https://doi.org/10.3892/etm.2017.4876
MLA
Yang, Q., Lu, T., Shu, C., Feng, L., Chang, H., Ji, Q."Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism". Experimental and Therapeutic Medicine 14.4 (2017): 3198-3206.
Chicago
Yang, Q., Lu, T., Shu, C., Feng, L., Chang, H., Ji, Q."Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism". Experimental and Therapeutic Medicine 14, no. 4 (2017): 3198-3206. https://doi.org/10.3892/etm.2017.4876